NCT02945813 is a Phase 2 clinical trial of Metformin in Prostate Cancer, sponsored by Swiss Cancer Institute.

Who is sponsoring NCT02945813?

NCT02945813 is sponsored by Swiss Cancer Institute.

What drugs are being tested in NCT02945813?

Interventions in NCT02945813: Metformin, Salvage Radiotherapy SRT.

What condition does NCT02945813 study?

NCT02945813 studies Prostate Cancer.

Is NCT02945813 still recruiting?

NCT02945813 is currently terminated. Last updated 14 April 2022.

Last reviewed 2022-04-14 · How we verify

NCT02945813

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy

Terminated Phase 2 Last updated 14 April 2022

What this trial tests

Phase 2 trial testing Metformin in Prostate Cancer in 112 participants. Terminated before completion.

Timeline

24 October 2017

Primary endpoint
28 February 2022

28 February 2022

Quick facts

Lead sponsor	Swiss Cancer Institute
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	112
Start date	24 October 2017
Primary completion	28 February 2022
Estimated completion	28 February 2022
Sites	27 locations across France, Switzerland, Germany

Drugs / interventions tested

Metformin (metformin) — full drug profile →
Salvage Radiotherapy SRT

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Swiss Cancer Institute

Who can join

Adults 18 to 75, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of the trial is to explore the efficacy of salvage radiotherapy (SRT) plus metformin compared to SRT in the endpoint of time to progression after prostatectomy failure.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
Xu Y, Xue D, Bankhead A, Neamati N. · · 2020 · cited 127× · PMID 33103432 · DOI 10.1021/acs.jmedchem.0c01013
Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy.
Li J, Eu JQ, Kong LR, Wang L, et al · · 2020 · cited 99× · PMID 33092283 · DOI 10.3390/molecules25204831
Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review.
Ahn HK, Lee YH, Koo KC. · · 2020 · cited 60× · PMID 33198356 · DOI 10.3390/ijms21228540
Targeting Mitochondrial OXPHOS and Their Regulatory Signals in Prostate Cancers.
Chen CL, Lin CY, Kung HJ. · · 2021 · cited 39× · PMID 34948229 · DOI 10.3390/ijms222413435
Targeting lipid metabolism in metastatic prostate cancer.
Scheinberg T, Mak B, Butler L, Selth L, et al · · 2023 · cited 31× · PMID 36743527 · DOI 10.1177/17588359231152839
Cancer Stem Cells: Metabolic Characterization for Targeted Cancer Therapy.
Kaur J, Bhattacharyya S. · · 2021 · cited 21× · PMID 34804950 · DOI 10.3389/fonc.2021.756888
Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio.
van Gisbergen MW, Zwilling E, Dubois LJ. · · 2021 · cited 11× · PMID 34041023 · DOI 10.3389/fonc.2021.653621
Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients.
Cailleteau A, Sargos P, Saad F, Latorzeff I, et al · · 2021 · cited 4× · PMID 35004302 · DOI 10.3389/fonc.2021.780507

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Swiss Cancer Institute trials

Trials by the same sponsor.

NCT07158489 — Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC · Phase 2 · not yet recruiting
NCT06835049 — Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue · Phase 2 · recruiting
NCT06452394 — NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline · Phase 2 · recruiting
NCT06114108 — Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients · NA · recruiting
NCT04629781 — Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02945813 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swiss Cancer Institute
Last refreshed: 14 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02945813.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing